First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer

By D. Carbone. 2017

961 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/222195858f85911018a4a02159f398798b093a44

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (2019, methodology): “gov identifier: NCT02041533) study did not improve PFS or OS among patients with previously untreated advanced NSCLC with PD-L1 expression of 5% or greater.(15) Although cross-trial comparisons should be approached with caution, different PD-L1 assays (with different anti–PD-L1 antibodies) and thres”
Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer (2018, neutral): “Tumor mutational burden was defined as the total number of somatic missense mutations, and patients were divided into tertiles, as done previously (Carbone et al., 2017).”
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, neutral): “KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “In patients with advanced cancers treated with PD-1 blockade monotherapy, multiple reports across multiple tumor types (Carbone et al., 2017; Le et al., 2017; Rizvi et al., 2015; Rosenberg et al., 2016; Snyder et al., 2014; Van Allen et al., 2015) have identified an association between increased TMB”
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “survival (PFS) in patients with PD-L1 expression >5% [42, 73].”
Digital pathology and artificial intelligence in translational medicine and clinical practice (2021, result): “1) 3,4 .”
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018, background): “and PD-L1 expression were independent variables that both associated with benefit as previously seen.(11) It seems that TMB is similarly meaningful as PD-L1 expression,”
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, result): “archival tissue biopsy, subsequent immunotherapy in the standard of care arms, and outperformance or overachievement of study assumptions by standard of care therapies have been among the many, but not all, potential explanations for these recent results [89, 90, 92, 93].”